ReNeuron touts promising results from stem cell trial

05/17/2013 | Bloomberg

Researchers are set to announce positive results from a trial of ReNeuron Group's stem cell treatment for the damage caused by stroke, CEO Michael Hunt said. The findings are expected to be presented this month at a conference in London. "It sets us up nicely for a Phase II efficacy trial," said Hunt.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ